药物广泛研究:探索药物使用10年前的炎症性肠病诊断
Linéa Bonfils1, Anastasia Karachalia Sandri1, Gry J Poulsen1
1Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
The American journal of gastroenterology
|July 6, 2023
概括
患有炎症性肠病 (IBD) 的人在诊断前10年使用了更多的处方药,特别是在克罗恩病 (CD) 中. 这表明IBD诊断之前有广泛的多器官参与.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 对炎症性肠病 (IBD) 的预诊断阶段越来越感兴趣.
- 了解IBD和其他疾病之间的重叠.
- 在IBD诊断之前调查药物使用模式.
研究的目的:
- 为了比较在诊断前10年的IBD和无IBD患者之间的处方药的使用情况.
- 确定与预诊断性IBD相关的特定药物类别.
- 探索IBD亚型,特别是克罗恩病 (CD) 中预诊断药物使用的差异.
主要方法:
- 丹麦全国范围的登记册用于识别29219名IBD患者,292190名匹配IBD-free对照.
- 主要结局:在诊断/匹配前的10年内使用任何处方药 (≥1个赎回的处方).
- 世界卫生组织解剖治疗化学 (ATC) 主要组和子组分析的药物使用情况.
主要成果:
- 与对照人群相比,IBD人口在诊断前10年内普遍增加了药物使用.
- 在IBD患者的14个ATC主要组中的12个中,药物使用率高出1.1至1.8倍 (P < 0.0001).
- 克罗恩氏病 (CD) 患者在诊断前10年使用免疫抑制剂 (2.7倍),抗贫血药 (2.3倍),止痛药 (1.9倍) 和精神病药 (1.9倍) 显著增加 (P < 0.0001).
结论:
- 增加药物使用是IBD,特别是CD的预诊断阶段的一贯发现.
- 这些发现表明,在IBD诊断之前的几年里,多器官参与.
- 药物治疗模式可以提供有关早期疾病检测和管理策略的见解.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
155
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
155
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
200
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
200
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
357
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
357
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
156
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
156
Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175


